 |
Shanghai, China; Cambridge, Massachusetts, USA; and Rotterdam, NetherlandsJune 15, 2026 /PRNewswire/ — Harbour BioMed (Stock Code: 02142.HK), a global biopharmaceutical company focused on the discovery and development of innovative antibody therapies in immunology, oncology, and other therapeutic areas, and BioMap, a global leader in life science foundational models, today jointly announced the establishment of a multi-layered, long-term comprehensive strategic partnership. The collaboration will focus on AI-driven research and development of complex macromolecular drugs, aiming to systematically address the bottlenecks and challenges in developing next-generation innovative therapies and jointly build a globally competitive R&D ecosystem.
Under the strategic cooperation framework, both parties will jointly establish a new AI-driven pipeline R&D company targeting the global market—MegaStream TechBio. This company will integrate “exclusive big data × proprietary large models × large-scale innovative pipeline portfolios” to build an AI R&D engine centered on a new-generation intelligent closed-loop wet-dry experimental platform and personalized, multimodal, multi-attribute generative large models. The focus will be on major unmet clinical needs in cardiovascular, renal, anti-aging, oncology, and other areas, with First-in-Class (FIC) and Best-in-Class (BIC) as core benchmarks. The goal is to develop next-generation, globally competitive, cutting-edge complex macromolecular drugs and drive differentiated innovative pipelines into clinical stages in batches, striving to become a global leader in AI-driven complex macromolecular drug R&D.
Harbour BioMed will act as the lead initiator, opening its globally unique fully human antibody platform, deep target biology expertise, and global clinical development advantages to MegaStream. BioMap will serve as the co-initiator, providing underlying AI technology empowerment, model engineering support, and intelligent R&D capabilities to help the company rapidly advance pipeline development. MegaStream’s initial pipeline will consist of AI drug R&D projects from prior collaborations between the two parties and newly initiated AI-native pipeline R&D projects. The initiators will enjoy potential upfront payments, success milestones, and royalty sharing in line with industry practices. Meanwhile, MegaStream’s core management team will be jointly formed by senior executives from multinational pharmaceutical companies and renowned experts in the artificial intelligence field, with personnel currently being assembled.
As co-initiators of MegaStream TechBio, Harbour BioMed and BioMap will jointly advance three core strategic deployments:
I. Establish a Globally Leading Proprietary AIDD Infrastructure Platform, Defining the Next-Generation Engineering Paradigm for Complex Macromolecules
Both parties will build a globally leading AI-driven AIDD infrastructure platform for complex macromolecular drugs for MegaStream. This platform will be based on BioMap’s leading life science foundational model platform, xTrimo, and the vast, high-quality data accumulated from Harbour BioMed’s unique Harbour Mice® fully human antibody platform.
In this powerful collaboration, BioMap will leverage its life science foundational model capabilities, combined with the high-quality, full-scale data provided by Harbour BioMed, to systematically and specifically train, optimize, and iterate models tailored to the distinct characteristics of complex macromolecular drugs compared to traditional general proteins and antibodies. This will result in a continuously self-evolving, personalized proprietary MegaStream large model. As the company’s AI foundation, this model will be deeply optimized for next-generation complex macromolecule types, including multi-specific antibodies, XDC conjugates, in vivo CAR-T, and inhaled/oral macromolecular drugs, offering powerful performance advantages and enabling one-stop AI design capabilities from sequence generation to developability optimization.
II. Jointly Build a New-Generation Intelligent High-Throughput Closed-Loop Wet-Dry Laboratory, Providing Closed-Loop Assurance for Efficient Validation and Continuous Data Accumulation of AI-Native Molecules
Based on the MegaStream large model, both parties will combine Harbour BioMed’s extensive proprietary experimental technical capabilities with BioMap’s BioMap OS discovery system’s advantages in high-throughput closed-loop wet-dry laboratory scheduling management, automated data analysis, data management, and model iteration to build a new-generation intelligent high-throughput closed-loop wet-dry laboratory.
This laboratory will be designed to meet the training and validation needs of various biological attribute parameter models for complex macromolecular drugs, as well as the practical requirements for data accumulation and model iteration during drug R&D. It will build a globally leading intelligent control center and experimental capability system, achieving breakthroughs in four core capabilities: fully intelligent scheduling, high-performance experimental validation, full-scale automated data collection and analysis, and efficient AI modeling and model evolution, forming a fully automated closed loop of “design-build-test-learn.”
Once completed, this AI-native intelligent laboratory is expected to improve efficiency by over 500% compared to the previous generation of closed-loop wet-dry laboratories, significantly accelerating the discovery and iteration pace of complex macromolecular drugs. This will provide strong support for a fundamental paradigm shift in R&D and the continuous optimization of AI model capabilities. Additionally, the laboratory will increase data accumulation efficiency by more than tenfold, generating over 5PB of high-quality AI-Ready life science data within the next five years, driving rapid and effective evolution of AI models.
III. Empower the Scaling of Next-Generation Pipeline R&D Portfolios, Achieving an End-to-End Closed Loop from “AI Generation” to “Clinical Value”
The first collaborative FIC pipeline R&D project driven by AI and biotechnology between the two parties began in 2021. In over 10 subsequent pipeline projects, AI has been continuously applied to empower key R&D stages such as property prediction, optimization, and generative design. In the future, leveraging the newly built next-generation AI complex macromolecular drug R&D platform, the R&D capabilities for FIC/BIC pipelines will be significantly enhanced, providing solid support for Harbour BioMed and MegaStream to advance hundreds of innovative pipeline projects in parallel. By replacing traditional repetitive screening experiments with AI model predictions combined with a small number of high-precision validations, and leveraging the generative prediction advantages of large models, the platform will produce high-level pipeline molecules with superior performance indicators, more comprehensive property optimization, and more precise programmable regulation capabilities. In the coming years, both parties will accelerate the clinical translation of existing pipelines and new FIC/BIC pipelines, creating an industry-leading complete value chain closed loop from AI R&D to clinical implementation.
Dr. Wang Jinsong, Founder, Chairman, and CEO of Harbour BioMed, and Chairman of MegaStream TechBio, stated: “The strategic partnership between Harbour BioMed and BioMap marks a new phase in AI-driven biomedical innovation. Harbour possesses a globally leading fully human antibody technology platform and over a decade of accumulated unique, high-quality antibody data, while BioMap has a hundred-billion-parameter life science foundational model and AI computing platform. This powerful collaboration not only validates and upgrades our previous successful cooperation but will also systematically enhance the speed and success rate of developing next-generation innovative complex macromolecular drugs globally. MegaStream will complete its company formation and the execution of its initial pipelines in the shortest possible time, running a practical closed loop from AI design to clinical validation. We also look forward to exploring new industry opportunities with global long-term partners and renowned investment institutions.”
Liu Wei, Co-founder and CEO of BioMap, stated: “Since its inception, BioMap has been committed to building cutting-edge AI prediction capabilities in the life sciences field and helping pharmaceutical companies create complete platforms that support the generative discovery of large-scale FIC projects and joint prediction and optimization of multiple attribute parameters from early research to preclinical stages. Harbour BioMed is a benchmark company in the global fully human antibody field. Its Harbour Mice® platform and Hu-mAtrIx™ AI platform represent the cutting edge of antibody engineering and AI integration. This strategic partnership combines BioMap’s large model capabilities with Harbour’s unique data assets and deep drug development experience to create a trinity generative AI infrastructure for biomedical R&D. We believe this infrastructure will demonstrate immense value through the successful R&D of large-scale FIC pipelines and set a new paradigm-level benchmark for AI applications in the entire industry.”
About Harbour BioMed
Harbour BioMed (Stock Code: 02142.HK) is a global biopharmaceutical company focused on the discovery and development of innovative drugs in immunology, oncology, and other therapeutic areas. The company rapidly expands its innovative drug R&D pipeline through independent R&D, joint development, and diversified international collaborations.
Harbour BioMed’s proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both heavy-chain-only (HCAb) and conventional dual-light-chain (H2L2) formats. The immune cell engager (HBICE®) developed based on the HCAb antibody platform can achieve anti-tumor efficacy unattainable by traditional drug combination therapies. Additionally, the HCAb PLUS™ technology, developed based on the HCAb antibody platform, provides comprehensive new molecular solutions for innovative multi-specific drug development in different disease areas. Furthermore, leveraging the Harbour Mice® platform, Harbour BioMed has launched the first fully human AI HCAb model driven by its Hu-mAtrIx™ artificial intelligence (AI) platform—a fully human HCAb generation and screening model—to accelerate the development of innovative therapies.
Harbour Mice®, HBICE®, HCAb PLUS™, single B-cell cloning screening platform, and AI technology together form Harbour’s next-generation innovative therapeutic antibody R&D engine. For more information, please visit: www.harbourbiomed.com.
About BioMap
BioMap is a global leader in life science foundational models, dedicated to building a new generation of AI infrastructure for the life science industry to enhance discovery efficiency.
BioMap’s independently developed 268-billion-parameter life science foundational model, xTrimo, achieves more accurate AI prediction capabilities by decoding the underlying laws of genes, proteins, cells, and biological systems. It has achieved state-of-the-art (SOTA) performance in over 300 prediction tasks across more than 20 life science subfields and won honors such as the overall championship in the inaugural World Virtual Cell Competition.
The company’s life science discovery system, BioMap OS, built on the foundational model, helps users establish systematic AI capabilities. Through AI-driven closed-loop wet-dry discovery, it enables innovative tasks such as data insight, parameter optimization, and generative design, while helping users accumulate their own data and train their own AI models to continuously improve their AI proficiency. Currently, BioMap supports over 800 institutional users globally, covering multiple vertical fields including antibodies and innovative proteins, innovative therapies and precision medicine, synthetic biology, and cutting-edge research. For more information, please visit: www.biomap.com.